Adma Biologics Inc (NASDAQ: ADMA) on Friday, soared 2.55% from the previous trading day, before settling in for the closing price of $19.20. Within the past 52 weeks, ADMA’s price has moved between $8.91 and $25.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 71.73%. The company achieved an average annual earnings per share of 31.94%. With a float of $230.39 million, this company’s outstanding shares have now reached $238.53 million.
Considering the fact that the conglomerate employs 685 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 52.55%, operating margin of 33.1%, and the pretax margin is 30.64%.
Adma Biologics Inc (ADMA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adma Biologics Inc is 3.49%, while institutional ownership is 86.25%. The most recent insider transaction that took place on May 15 ’25, was worth 408,450. In this transaction President and CEO of this company sold 21,000 shares at a rate of $19.45, taking the stock ownership to the 2,049,850 shares. Before that another transaction happened on Apr 15 ’25, when Company’s President and CEO sold 21,000 for $21.46, making the entire transaction worth $450,660. This insider now owns 2,055,850 shares in total.
Adma Biologics Inc (ADMA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 31.94% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Adma Biologics Inc (ADMA) is currently performing well based on its current performance indicators. A quick ratio of 3.36 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.23. Likewise, its price to free cash flow for the trailing twelve months is 51.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.84, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.98 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Compared to the last year’s volume of 3.22 million, its volume of 3.6 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 13.19%. Additionally, its Average True Range was 1.41.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 50.86%, which indicates a significant increase from 16.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.56% in the past 14 days, which was lower than the 61.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.34, while its 200-day Moving Average is $18.32. Nevertheless, the first resistance level for the watch stands at $20.03 in the near term. At $20.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.77. If the price goes on to break the first support level at $19.29, it is likely to go to the next support level at $18.89. Should the price break the second support level, the third support level stands at $18.55.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
Market capitalization of the company is 4.70 billion based on 238,734K outstanding shares. Right now, sales total 426,450 K and income totals 197,670 K. The company made 114,800 K in profit during its latest quarter, and 26,900 K in sales during its previous quarter.
